Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Buddy Creech

Showing results (91-100 of 143) with videos related to

Pageof 15
Sort By:
The Journal of Infectious Diseases|July 23, 2016
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster VaccinationDaniel F Hoft, Kathleen Lottenbach, Johannes B Goll, et al.
Mbio|February 6, 2025
Structural mapping of polyclonal IgG responses to HA after influenza virus vaccination or infectionAndré Nicolás León, Alesandra J Rodriguez, Sara T Richey, et al.
Biorxiv : the Preprint Server for Biology|July 19, 2024
Structural Mapping of Polyclonal IgG Responses to HA After Influenza Virus Vaccination or InfectionAndré Nicolás León, Alesandra J Rodriguez, Sara T Richey, et al.
The Pediatric Infectious Disease Journal|September 16, 2014
Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in childrenKaren L Kotloff, Natasha B Halasa, Christopher J Harrison, et al.
Vaccine|August 4, 2019
Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescentsFlor M Munoz, Evan J Anderson, David I Bernstein, et al.
Vaccine|December 6, 2016
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 studyRobert W Frenck, C Buddy Creech, Eric A Sheldon, et al.
Journal of Clinical Pharmacology|December 4, 2024
Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill PatientsJoshua A Reeder, C Buddy Creech, Roger L Nation, et al.
NPJ Vaccines|August 11, 2025
Systems biology-based assessment of immune responses to whole cell and acellular pertussis vaccinesMariana Leguia, Antón Vila-Sanjurjo, Diana Juarez, et al.
Hospital Pediatrics|January 5, 2023
Using Administrative Billing Codes to Identify Acute Musculoskeletal Infections in ChildrenJustin B Searns, John D Rice, Kaitlyn B Bertin, et al.
Vaccine|November 22, 2016
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trialC Buddy Creech, Robert W Frenck, Eric A Sheldon, et al.
Pageof 15

Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
The Journal of Infectious Diseases|July 23, 2016
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster VaccinationDaniel F Hoft, Kathleen Lottenbach, Johannes B Goll, et al.
Mbio|February 6, 2025
Structural mapping of polyclonal IgG responses to HA after influenza virus vaccination or infectionAndré Nicolás León, Alesandra J Rodriguez, Sara T Richey, et al.
Biorxiv : the Preprint Server for Biology|July 19, 2024
Structural Mapping of Polyclonal IgG Responses to HA After Influenza Virus Vaccination or InfectionAndré Nicolás León, Alesandra J Rodriguez, Sara T Richey, et al.
The Pediatric Infectious Disease Journal|September 16, 2014
Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in childrenKaren L Kotloff, Natasha B Halasa, Christopher J Harrison, et al.
Vaccine|August 4, 2019
Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescentsFlor M Munoz, Evan J Anderson, David I Bernstein, et al.
Vaccine|December 6, 2016
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 studyRobert W Frenck, C Buddy Creech, Eric A Sheldon, et al.
Journal of Clinical Pharmacology|December 4, 2024
Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill PatientsJoshua A Reeder, C Buddy Creech, Roger L Nation, et al.
NPJ Vaccines|August 11, 2025
Systems biology-based assessment of immune responses to whole cell and acellular pertussis vaccinesMariana Leguia, Antón Vila-Sanjurjo, Diana Juarez, et al.
Hospital Pediatrics|January 5, 2023
Using Administrative Billing Codes to Identify Acute Musculoskeletal Infections in ChildrenJustin B Searns, John D Rice, Kaitlyn B Bertin, et al.
Vaccine|November 22, 2016
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trialC Buddy Creech, Robert W Frenck, Eric A Sheldon, et al.
Pageof 15